The World’s First Autonomous Blood Drawing Device

Projektinformationen

VD-1

ID Finanzhilfevereinbarung: 190176843

DOI

10.3030/190176843

Projekt abgeschlossen

EK-Unterschriftsdatum 14 Juli 2023

Startdatum 1 Juni 2023

Enddatum 28 Februar 2025

Finanziert unter

• The European Innovation Council (EIC)

Gesamtkosten

€ 2 975 301,25

EU-Beitrag

€ 2 082 710,88

Koordiniert durch

VITESTRO BV
Netherlands

Periodic Reporting for period 2 - VD-1 (The World’s First Autonomous Blood Drawing Device)

Berichtszeitraum: 2024-04-01 bis 2025-02-28

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Vitestro has created the first fully-autonomous device that draws blood from patients. Our solution, called VD-1, performs the whole
venipuncture procedure, from vein detection to bandage application, without any human intervention. We have fully developed our
technology in-house and protected it with seven patents. More than 2,500 patients have tried our solution: the user acceptance, first-time
success rate, and hemolysis rate are comparable to those measured using human nurses. The VD-1 will mitigate the chronic shortage
of healthcare personnel. It will also standardize the venipuncture process, which has been substantially unchanged for decades. We target
two categories of customers – lab chains and hospital labs – and we have launching customers in both of them. Vitestro has a team of
over 70 people, including technical, medical, regulatory, and commercial expertise.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

- We worked on the A.D.O.P.T. Trial, which is the largest trial in autonomous blood drawing worldwide.
- We enrolled the first 1,400 patients in 4 European Hospital Laboratory sites.
- We have completed the technology objectives, increase safety and performance and preparing the device for industrialization.
- We have solved multiple technical challenges in integration of hardware and software.
- We have obtained CE marking and can thereby sell the device within the EU.
- We have placed the first two devices in a commercial setting in the OLVG hospital in Amsterdam

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

- We have raised a Series A-1 funding round of €20M with a consortium of multiple EU and U.S. partners, including EIC Fund
- We have presented trial results at Dutch congress NVKC as well as NVML
- We have signed contracts with 5 different customers for a total of 13 devices
- We have grown the team from 50 to ~100 people
- We have participated as a semi-finalist in the ADLM Disruptive Innovation Award
- We have a total of nine patents filed on all essential parts of the device